Zepbound vs Wegovy: Which GLP-1 Medication Works Better for Weight Loss?

Sarah had been researching weight loss medications for weeks when she finally asked her doctor the question that stumped even him: "Between Zepbound and Wegovy, which one actually works better?" It's a fair question. Both medications have flooded social media feeds and news headlines with dramatic before-and-after photos, but when you're considering starting a GLP-1 medication that you'll potentially take for months or years, you want real data, not just hype.

The truth is both medications are remarkably effective, but they work differently, and recent clinical trials suggest one may deliver slightly better results for the average patient. Let's break down what the science actually tells us.

How These Medications Actually Work in Your Body

Wegovy contains semaglutide, which targets a single hormone receptor called GLP-1. It mimics a naturally occurring hormone your gut releases after eating, telling your brain you're full and slowing how quickly food leaves your stomach. The result? You feel satisfied with less food, and you're not constantly thinking about your next meal.

Zepbound takes a different approach. Its active ingredient, tirzepatide, is what researchers call a dual agonist. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. Think of it as hitting two targets instead of one. That GIP component appears to enhance the weight loss effects beyond what GLP-1 does alone, though scientists are still working out exactly why the combination is so powerful.

In our clinical experience, patients often ask whether this dual action means Zepbound is automatically better. Not necessarily. What it does mean is that the two medications work through slightly different mechanisms, which can translate to different results and different side effect profiles.

Both drugs come as weekly injections you give yourself, typically in your abdomen, thigh, or upper arm. You start at a low dose and gradually increase over several months. This slow titration helps your body adjust and minimizes side effects like nausea, which we'll get to in a moment.

The dosing schedules differ slightly. Wegovy maxes out at 2.4 mg weekly, while Zepbound can go up to 15 mg weekly. But don't let those numbers confuse you—they're different medications with different potencies, so you can't compare milligrams directly. It's like comparing ounces of wine to ounces of beer; the volume doesn't tell the whole story.

What the Clinical Trials Actually Show

Here's where things get interesting. The SURMOUNT-1 trial, which tested Zepbound in over 2,500 adults with obesity, found that participants lost an average of 20.9% of their body weight on the highest dose over 72 weeks. That's remarkable. For someone starting at 240 pounds, we're talking about losing roughly 50 pounds.

The STEP 1 trial evaluated Wegovy in a similar population. Participants on the 2.4 mg dose lost an average of 14.9% of their body weight over 68 weeks. Still impressive, but noticeably less than what Zepbound achieved.

Those numbers have held up in real-world use too. We see patients on Zepbound frequently hitting that 20-25% weight loss mark when they stick with the medication and make basic lifestyle changes. Wegovy patients typically land in the 15-20% range. Both outcomes beat anything we've seen from previous weight loss medications, which typically delivered 5-10% weight loss at best.

But here's something the headlines often miss: individual responses vary wildly. Some people respond better to semaglutide, others to tirzepatide. In SURMOUNT-1, about 63% of participants lost at least 20% of their body weight. In STEP 1, about 50% lost at least 15%. These aren't small differences, but they also mean plenty of people succeed on either medication.

One head-to-head comparison study published in 2024 directly compared the two drugs in over 1,800 patients. After one year, those on tirzepatide (Zepbound) lost an average of 5.9% more body weight than those on semaglutide (Wegovy). The difference was statistically significant and clinically meaningful—enough that you'd likely notice it when you step on the scale or buy clothes.

Side Effects: What You'll Actually Experience

Let's be honest about side effects, because they're the main reason people stop these medications. Both Zepbound and Wegovy can cause gastrointestinal issues. Nausea tops the list, followed by diarrhea, constipation, vomiting, and stomach pain.

In the clinical trials, about 44% of people on Wegovy reported nausea, compared to 33% on the highest dose of Zepbound. That might make Zepbound sound better, but the reality is more nuanced. Zepbound has a slightly higher rate of diarrhea—about 23% compared to 20% with Wegovy.

Most side effects are worst during the first few weeks after starting or increasing your dose. Your body typically adjusts within a week or two. We tell our patients to start the medication on a Thursday or Friday, so if they do feel rough, it happens over the weekend when they're not trying to sit through work meetings.

There are some practical tricks that help. Eating smaller, more frequent meals works better than three large ones. Avoiding greasy, fried, or very rich foods during the adjustment period prevents a lot of misery. Staying well-hydrated is crucial, especially if you're dealing with diarrhea or vomiting.

Serious side effects are rare but possible with both medications. These include pancreatitis, gallbladder problems, and potential thyroid tumors (seen in rodent studies but not confirmed in humans). Both medications carry a black box warning about thyroid C-cell tumors and shouldn't be used if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

One interesting difference: in our clinical experience, patients on Zepbound seem to report less nausea overall, but when they do get side effects, diarrhea tends to be more bothersome. With Wegovy, nausea is more common but often manageable with the strategies we mentioned.

Cost, Insurance, and Accessibility

Here's where the conversation gets frustrating for many patients. Both medications carry list prices around $1,000-$1,400 per month without insurance. That's not a typo. For many people, that's rent money or a car payment.

Insurance coverage is improving but inconsistent. Some plans cover these medications for weight loss, others only for diabetes (both drugs have diabetes versions—Ozempic for semaglutide, Mounjaro for tirzepatide), and many don't cover them at all. Even when insurance does cover them, prior authorization requirements can delay treatment by weeks or months.

Manufacturer savings programs can reduce costs dramatically if you have commercial insurance. Novo Nordisk offers a savings card for Wegovy that can lower your copay to $25 per month. Eli Lilly has a similar program for Zepbound. But these programs typically exclude Medicare, Medicaid, and other government insurance.

That's where compounded versions enter the picture. Compounding pharmacies can create semaglutide and tirzepatide formulations that cost a fraction of the brand-name price—often $99-$299 per month. These aren't generic versions (those don't exist yet), but rather custom-mixed preparations made by licensed pharmacies under FDA regulations.

Accessibility has been an issue too. Both medications have faced supply shortages over the past two years as demand skyrocketed. Wegovy had particularly severe shortages in 2022 and 2023, leaving many patients unable to refill prescriptions. Zepbound launched later and has had better supply consistency, though availability still varies by pharmacy and region.

What Women Should Know

Women made up the majority of participants in both SURMOUNT-1 and STEP 1 trials, and the results were consistent across genders. However, women do need to consider some specific factors. If you're of childbearing age, both medications require reliable contraception. You should stop taking either medication at least two months before trying to conceive, as the effects on pregnancy aren't well studied.

Some women report that these medications affect their menstrual cycles, particularly in the first few months. This isn't an official side effect listed in the prescribing information, but we hear about it frequently enough that it's worth mentioning. The changes usually normalize as your body adjusts.

Women with PCOS have reported particularly good results with both medications. The weight loss can help regulate cycles and improve insulin sensitivity, addressing some of the root metabolic issues that drive PCOS symptoms.

What Men Should Know

Men typically lose weight slightly faster on these medications than women do, likely due to differences in body composition and metabolism. The clinical trials showed similar percentage losses, but men often hit their goals a few weeks earlier.

One concern we hear from men: will this affect testosterone or muscle mass? The research shows these medications don't directly impact testosterone levels. However, rapid weight loss from any source can temporarily affect hormone levels. That's why we emphasize resistance training and adequate protein intake to preserve muscle while you're losing weight.

Some men worry about the injection aspect—there's still a stigma around needles for some people. The injections use very thin needles (about the size of an acupuncture needle) and most patients tell us they barely feel them after the first couple of times.

From the Ozari Care Team

We recommend looking beyond just the weight loss numbers when choosing between these medications. Consider your insurance coverage, your history with gastrointestinal issues, and honestly assess whether you're prepared for a weekly injection long-term. In our experience, the best medication is the one you'll actually stick with. Some patients do better knowing they're on the "stronger" option, while others prefer starting with semaglutide and potentially switching later if needed. What we tell our patients is this: both medications can be life-changing when combined with sustainable lifestyle changes, and neither is a magic bullet that works without effort on your part.

Key Takeaways

• Zepbound (tirzepatide) produces slightly better weight loss results on average—about 21% total body weight compared to 15% with Wegovy (semaglutide) in clinical trials
• Both medications cause similar gastrointestinal side effects, with Wegovy showing higher nausea rates (44% vs 33%) and Zepbound higher diarrhea rates (23% vs 20%)
• Individual responses vary significantly; some people respond better to one medication over the other regardless of average trial results
• Brand-name versions of both drugs cost $1,000+ monthly, but compounded versions and manufacturer savings programs can dramatically reduce out-of-pocket costs
• Both medications require weekly injections, gradual dose increases, and long-term commitment for sustained results

Frequently Asked Questions

Can I switch from Wegovy to Zepbound if I'm not losing enough weight?

Yes, many patients successfully switch between these medications, and doctors frequently make this change when someone isn't responding as hoped to their current treatment. Your provider will need to determine the equivalent dose when switching, and you'll likely experience some side effects during the transition as your body adjusts to the new medication. Most insurance companies or treatment programs require that you've been on one medication for at least 3-4 months before switching, to give it a fair trial.

Which medication has fewer side effects overall?

The side effect profiles are remarkably similar, though the specifics differ slightly between individuals. Zepbound tends to cause less nausea but slightly more diarrhea, while Wegovy has higher nausea rates but may be gentler on your digestive system in other ways. About 5-7% of people discontinue either medication due to side effects, so the vast majority do tolerate them well enough to continue. Starting at the lowest dose and increasing slowly gives your body time to adjust and minimizes problems.

Will I regain weight if I stop taking these medications?

Most research shows that people do regain some weight after stopping GLP-1 medications, typically about two-thirds of what they lost over the following year. This isn't a failure of willpower—these medications change your hunger hormones, and when you stop, those hormones shift back. That said, people who've built solid lifestyle habits during treatment and who stop gradually rather than abruptly tend to maintain more of their weight loss. Think of these medications as a tool that works best alongside permanent changes to eating patterns and activity levels.

Do these medications work if I don't have diabetes?

Absolutely. Both Zepbound and Wegovy are specifically FDA-approved for weight loss in people without diabetes. You do need to meet certain criteria—typically a BMI of 30 or higher, or 27 or higher with a weight-related health condition like high blood pressure or sleep apnea. The clinical trials that led to FDA approval were conducted primarily in people without diabetes, and the results were excellent. If you do have diabetes, there are different versions of the same active ingredients (Ozempic and Mounjaro) that are approved and covered for diabetes treatment.

How long do I need to take these medications to maintain results?

Current evidence suggests these medications work best as long-term treatments, similar to how you'd take medication for high blood pressure or cholesterol. Most people reach their maximum weight loss between 60-72 weeks, and continuing the medication helps maintain that loss. Some patients do successfully stop after 1-2 years and maintain their weight through lifestyle alone, but this requires significant commitment to diet and exercise habits. We typically recommend planning for at least a year of treatment and then reassessing with your doctor whether you're ready to try maintaining without medication.

Making Your Decision

Choosing between Zepbound and Wegovy isn't always straightforward, despite Zepbound's slight edge in clinical trial results. Your insurance coverage might make one dramatically more affordable than the other. Your personal tolerance for specific side effects matters. Some people simply respond better to one medication over the other for reasons we don't fully understand yet.

What we do know is that both medications represent a genuine breakthrough in weight management. They're not perfect—the side effects are real, the cost is substantial, and they require long-term commitment. But for people who've struggled with obesity and weight-related health issues for years, these medications can be genuinely transformative.

The best approach is to have an honest conversation with a healthcare provider who understands these medications. Discuss your weight loss goals, your medical history, your budget, and your concerns. In many cases, starting with either medication and being willing to switch if needed makes more sense than agonizing over which one to try first.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, shipped to your door. Learn more at ozarihealth.com.